NielsenIQ Sets the Pace for the Omnichannel Measurement Revolution
28.9.2021 15:00:00 EEST | Business Wire | Press release
NielsenIQ, the industry leader in global measurement and data analytics, announced today two key acquisition agreements --Data Impact and Rakuten Intelligence. These acquisitions will drive significant value to NielsenIQ’s e-commerce and omnichannel measurement solutions and allow the company to revolutionize the consumer and retail measurement industries with a comprehensive view of the online marketplace, from product distribution to sales.
Today, e-commerce sales account for 12% of CPG sales in the U.S. and up to 30% of sales in global markets and are estimated to grow at a 15% CAGR through 2025. With significant growth and share from online-focused retailers, it has become more important to understand the total marketplace. Nevertheless, current e-commerce measurement is highly fragmented, with multiple, disparate offerings that do not allow an integrated and consistent view of the total market.
These acquisitions and suite of omnichannel measurement solutions uniquely position NielsenIQ to provide retailers and manufacturers with a harmonized, granular, and consistent view across channels, allowing them to anticipate trends, understand, and react faster to consumer needs and expectations.
“Measuring e-commerce is a top strategic imperative for NielsenIQ,” said Natalie Williams, Head of North America Measurement Product Leadership, NielsenIQ. “Together we can transform the way we measure e-commerce sales and how fast the shopper journey evolves by delivering powerful machine learning-driven insights to our clients around the world.”
The agreement to acquire Data Impact, a leading e-commerce intelligence player in 40 markets mainly across Europe and the U.S., will supercharge NielsenIQ’s omnichannel service. Combining Data Impact’s best-in-class technology - which provides a hypergranular view of banner and store-level e-commerce insights - with NielsenIQ’s unmatched retail measurement footprint, will enable NielsenIQ to scale Data Impact’s product offering globally; and most importantly, will position NielsenIQ to lead the future of omnichannel measurement and execution.
“Combining our technology with Data Impact’s unique offering enables us to offer manufacturers and retailers unparalleled, comprehensive coverage with the granularity needed to make winning omnichannel decisions,” said Jim Peck, Executive Chairman and CEO of NielsenIQ.
The acquisition of Rakuten Intelligence, three years after signing an exclusive agreement to combine Rakuten Intelligence’s largest e-commerce purchase panel in the U.S. with NielsenIQ’s retail sales data, will allow NielsenIQ to deliver our clients an integrated online and offline read, aligned to custom client hierarchies, underpinned by our cloud-based Connect platform. NielsenIQ’s recently launched Omnisales product is the first integration derived from this acquisition.
“We are proud to welcome these two champions into the NielsenIQ family. We will be able to provide a single number for online sales measurement through multi-sourced data - the truth the market needs - and we will also deliver e-commerce execution recommendations with unrivaled actionability. With unique scale and granularity, the landscape of opportunities is unlimited,” mentioned Clément Colin, Head of International E-commerce Measurement, NielsenIQ.
About NielsenIQ
NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.
Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.
NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com.
About Data Impact
Data Impact is one of the cutting-edge providers in omnichannel analytics solutions. The company uses localized data and AI algorithms to offer its customers various solutions, including location-based analytics, sales and shares estimates, media monitoring, SEO optimization, and more.
The Data Impact solution is already used by more than 150 companies in more than 40 countries. Launched in 2016, Data Impact is the only solution that offers FMCG manufacturers a precise visualization of their omnichannel distribution and the ability to identify localized levers of action.
About Rakuten Intelligence
Rakuten Intelligence is part of Rakuten Advertising, which connects leading agencies, brands and publishers to active and engaged consumers around the world. With access to Rakuten’s diverse media properties and audiences, combined with an award-winning performance network and proprietary consumer research, Rakuten Advertising creates the right conditions to reach new customers and sustain long-lasting loyalty.
Its foundation of advanced technology, data, and strategic services positions Rakuten Advertising to offer a differentiated suite of marketing and advertising solutions while continually pushing the industry forward. It is a division of Rakuten Inc., one of the world’s leading Internet service companies. The company is headquartered in San Mateo, CA, with offices throughout EMEA, APAC, LATAM, and North America. Learn more at www.rakutenadvertising.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005136/en/
Contact information
Media Relations:
(U.S. and English)
FERNANDA PAREDES, fernanda.paredes@nielseniq.com, +1-917-291-1196
GILLIAN MOSHER, gillian.mosher@nielseniq.com, +1-647-282-9714
(France) SEBASTIEN MONARD, sebastien.monard@nielseniq.com, +33-6-85-32-94-61
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom